世界过敏组织关于药物过敏/超敏反应诊断程序和治疗的国际调查,World Allergy Organization Journal

当前位置： X-MOL 学术 › World Allergy Organ. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

世界过敏组织关于药物过敏/超敏反应诊断程序和治疗的国际调查
World Allergy Organization Journal ( IF 3.9 ) Pub Date : 2011-01-01 , DOI: 10.1097/wox.0b013e31823dc02c
Bernard Yu-Hor Thong ₁ , Rita Mirakian , Mariana Castells , Werner Pichler , Antonino Romano , Patrizia Bonadonna , Deleanu Diana , Marek Kowalski , Anahi Yanez , Ramon Lleonart , Mario Sanchez-Borges , Pascal Demoly

Affiliation

目的研究世界过敏组织 (WAO) 成员在药物过敏/超敏反应中使用的诊断和治疗方式。方法在 6 月 29 日期间，以电子方式向 WAO 的成员协会、准成员协会以及区域和附属组织分发了一份包含 39 个问题的问卷, 2009 年和 2009 年 8 月 9 日。结果收到了八十二份答复。74.7%的人使用了皮肤测试，只有71.4%的人可以使用青霉素皮肤测试试剂。67.4% 使用体外特异性 IgE 试验，54.4% 使用嗜碱性粒细胞活化试验。36.8% 使用淋巴细胞转化试验，54.7% 使用斑贴试验。68.4% 的人使用了药物激发试验，最常见的适应症是排除超敏反应，其中病史/症状未提示药物超敏反应/过敏 (76.9%)。69.6% 的患者使用化疗、抗生素或生物制剂的快速脱敏。72.3% 的患者使用全身性皮质类固醇治疗 Stevens-Johnson 综合征，50.8% 的患者使用大剂量静脉注射免疫球蛋白治疗中毒性表皮坏死松解症。92.9% 的人在阿巴卡韦处方前进行人类白细胞抗原筛查，21.4% 的人在卡马西平处方前进行人白细胞抗原筛查。结论本次调查的结果形成了一个有用的框架，可用于开发教育和培训需求以及改善 WAO 成员获得药物过敏诊断和治疗方式的机会社团。72.3% 的患者使用全身性皮质类固醇治疗 Stevens-Johnson 综合征，50.8% 的患者使用大剂量静脉注射免疫球蛋白治疗中毒性表皮坏死松解症。92.9% 的人在阿巴卡韦处方前进行人类白细胞抗原筛查，21.4% 的人在卡马西平处方前进行人白细胞抗原筛查。结论本次调查的结果形成了一个有用的框架，可用于开发教育和培训需求以及改善 WAO 成员获得药物过敏诊断和治疗方式的机会社团。72.3% 的患者使用全身性皮质类固醇治疗 Stevens-Johnson 综合征，50.8% 的患者使用大剂量静脉注射免疫球蛋白治疗中毒性表皮坏死松解症。92.9% 的人在阿巴卡韦处方前进行人类白细胞抗原筛查，21.4% 的人在卡马西平处方前进行人白细胞抗原筛查。结论本次调查的结果形成了一个有用的框架，可用于开发教育和培训需求以及改善 WAO 成员获得药物过敏诊断和治疗方式的机会社团。

"点击查看英文标题和摘要"

A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity

ObjectiveTo study the diagnostic and treatment modalities used in drug allergy/hypersensitivity among members of the World Allergy Organization (WAO).MethodsA questionnaire comprising 39 questions was circulated electronically to member societies, associate member societies, and regional and affiliate organizations of WAO between June 29, 2009, and August 9, 2009.ResultsEighty-two responses were received. Skin testing was used by 74.7%, with only 71.4% having access to penicillin skin test reagents. In vitro-specific IgE tests were used by 67.4%, and basophil activation test was used by 54.4%. Lymphocyte transformation tests were used by 36.8% and patch tests by 54.7%. Drug provocation tests were used by 68.4%, the most common indication being to exclude hypersensitivity where history/symptoms were not suggestive of drug hypersensitivity/allergy (76.9%). Rapid desensitization for chemotherapy, antibiotics, or biologic agents was used by 69.6%. Systemic corticosteroid was used in the treatment of Stevens-Johnson syndrome by 72.3%, and high-dose intravenous immunoglobulins in toxic epidermal necrolysis by 50.8%. Human leukocyte antigen screening before prescription of abacavir was used by 92.9% and before prescription of carbamazepine by 21.4%.ConclusionsResults of this survey form a useful framework for developing educational and training needs and for improving access to drug allergy diagnostic and treatment modalities across WAO member societies.

更新日期：2011-01-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南